You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nash P, Ohson K, Walsh J on behalf of the ACTIVE investigators, et al
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Annals of the Rheumatic Diseases 2018;77:690-698.